BioNTech SE (NASDAQ: BNTX) has signed a strategic partnership contract with InstaDeep Ltd. Both the companies are planning to use the latest technologies such as machine learning and artificial intelligence to develop a cure for cancers and other infectious diseases. As per the deal, BNTX and InstaDeep will collaborate to make a Joint AI Innovation Lab in Germany, London, UK, and Mainz.

The technical expertise of InstaDeep and the capabilities of BNTX will be helpful in the development of cures for novel diseases. The partnership of the companies will focus on the main areas including Advanced Analytics, and Novel Drug Design. Lastly, BNTX has decided to enhance the supply chain and manufacturing processes.